• Bay 11-7085: Interpreting NF-κB Causality

  2026-09-25

  Bay 11-7085 is an NF-κB activation inhibitor that can help researchers test how inflammatory signaling relates to cell injury. This article connects ER-stress findings in subarachnoid hemorrhage research to practical experimental interpretation—without treating pathway inhibition as proof of a single mechanism.

• Topotecan in First-Line SCLC: Evidence and Limits

  2026-09-25

  David J. Stewart’s review evaluates topotecan-based combinations as potential first-line options for small cell lung cancer (SCLC), synthesizing promising phase II response rates alongside the key concern of neutropenia. It frames these regimens as investigational rather than established replacements for cisplatin–etoposide, and highlights the need for further comparative trials.

• GANT61 and the GLI2–Ferroptosis Connection

  2026-09-24

  GLI2 may connect Hedgehog-pathway activity to ferroptosis resistance in bladder cancer. This article examines the evidence, outlines how GANT61 can help test the biology, and sets practical boundaries for translating preclinical findings.

• FLT3-ITD Trafficking Limits ADC Activity in AML

  2026-09-24

  The study links FLT3-ITD receptor mislocalisation in MV4-11 leukaemia cells to weaker activity of an anti-FLT3 antibody-drug conjugate (ADC). Its findings suggest that receptor trafficking to lysosomes—not target recognition alone—can constrain payload delivery, highlighting a cell-context consideration for FLT3-targeted ADC design.

• Pexidartinib (PLX3397) in TAM Research

  2026-09-23

  Use Pexidartinib (PLX3397) to test how CSF1R inhibition changes macrophage survival and behavior in tumor models—not as a presumed direct SPP1 inhibitor. This workflow pairs dose-response and pathway readouts with viability-normalized SPP1 measurements to separate macrophage depletion from phenotypic change.

• 3-Bromopyruvate Overcomes Cetuximab Resistance

  2026-09-23

  This 2023 Cancer Gene Therapy study shows that combining 3-bromopyruvate with cetuximab suppresses colorectal cancer models that are intrinsically or adaptively resistant to cetuximab. The work identifies FOXO3a-dependent coordination of ferroptosis, autophagy, and apoptosis as a mechanistic basis for the combination effect.

• Fluorescein TSA Fluorescence System Kit for Astrocytes

  2026-09-22

  Translate transcriptomic astrocyte discoveries into spatially resolved validation with sensitive TSA labeling in tissue, cells, and ISH workflows. This guide explains how to amplify scarce regional or developmental markers while controlling background, deposition artifacts, and quantitative interpretation.

• Muscle-Derived BDNF in Early NMJ Formation

  2026-09-22

  Zhang and colleagues show that muscle-generated BDNF is transported to podosome-like structures, released in a calcium-dependent manner, and proteolytically processed to regulate early acetylcholine receptor clustering at neuromuscular synapses. The study connects subcellular BDNF localization with aneural and nerve-induced postsynaptic assembly, while providing a framework for separating intracellular furin activity from extracellular protease effects.

• Ibrexafungerp Activity at Vaginal pH

  2026-09-21

  The 2021 Sobel et al. study tested ibrexafungerp against 187 clinical Candida isolates under neutral and acidic conditions that model the vaginal environment. Its central finding was that activity was retained at pH 4.5, including against fluconazole-resistant isolates, supporting further evaluation of MK 3118 for vulvovaginal candidiasis while highlighting the need for clinical and formulation-based validation.

• MLN4924 HCl Salt: NAE Inhibition Guide

  2026-09-21

  MLN4924 HCl salt is a selective NEDD8-activating enzyme inhibitor for mechanistic studies of neddylation, cullin-RING ligases, protein degradation, and cell signaling. This guide connects its biochemical rationale with cancer biology research and carefully bounded studies of virus-induced RIPK3 degradation.

• BAPTA as a Causal Probe of Calcium Signaling

  2026-09-20

  BAPTA is a high-affinity calcium chelator that helps researchers test whether calcium flux is causally involved in apoptosis and cell signaling. This article translates recent IP3R/Ca2+/STAT3 evidence into practical assay-design decisions, controls, and interpretation strategies.

• TSA Mapping of BRAF-Driven Pain Signaling

  2026-09-19

  A translational framework for using tyramide signal amplification to visualize BRAF-associated synaptic remodeling and low-abundance molecular signals in neuropathic pain research.

• Dimetridazole Revives Cefotaxime Against MDR E. coli

  2026-09-18

  A 2025 Scientific Reports study shows that Dimetridazole can potentiate cefotaxime against a multidrug-resistant E. coli strain by compromising membrane integrity, permeability, and fatty-acid biosynthesis. The work combines checkerboard synergy testing, microscopy, lipid analysis, gene-expression measurements, and Galleria mellonella infection model research to connect phenotypic rescue with a membrane-centered mechanism.

• SpCas9 mRNA (ARCA, 5mCTP, ψUTP) for Reliable Editing

  2026-09-18

  Learn how SpCas9 mRNA (ARCA, 5mCTP, ψUTP), SKU R1006, can support more interpretable CRISPR-Cas9 experiments linked to cell viability, proliferation, and cytotoxicity assays. This scenario-based guide covers formulation, delivery controls, protocol optimization, data interpretation, and practical product selection.

• Electroporation for CRISPR Editing in Mouse Zygotes

  2026-09-17

  Hashimoto and Takemoto showed that electroporation can deliver Cas9 mRNA and guide RNA into mouse zygotes without removing the zona pellucida, providing a scalable alternative to embryo microinjection. Their optimized workflow supported both CRISPR/Cas9-mediated gene disruption and ssODN-mediated knock-in, while emphasizing the need to balance RNA uptake with embryo survival.

8334 records 1/556 page Next 12345 下5页 Last page